Cingulate to Participate in Benzinga All Live Access Event

Rhea-AI Summary

Cingulate (NASDAQ: CING) announced that Chairman and CEO Shane J. Schaffer, PharmD, will participate in a live Benzinga All Access event on August 28, 2024, at 10:30 a.m. CST. Schaffer will discuss the company's recent European patent, the ADHD market, and potential expansion of Cingulate’s Precision Timed Release™ (PTR™) drug delivery platform into other therapeutic areas. The event can be viewed live on Benzinga's YouTube channel and later on Cingulate's website.

KANSAS CITY, Kan., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer, PharmD, will participate in a live Benzinga All Access event on August 28, 2024, at 10:30 a.m. CST.

Along with a company overview, Dr. Schaffer will discuss Cingulate’s recently issued European patent, the state of the ADHD marketplace, as well as the potential expansion of Cingulate’s PTR platform into other therapeutic areas.

The event may be viewed live on Benzinga’s YouTube channel, Benzinga All Access, and will also be available for viewing on Cingulate’s website at cingulate.com/investors

About Cingulate®
Cingulate Inc. (NASDAQ: CING), is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders.
Cingulate is headquartered in Kansas City. For more information
visit Cingulate.com

Investor Relations
Thomas Dalton
Head of Investor & Public Relations, Cingulate
TDalton@cingulate.com
913-942-2301

Matt Kreps
Darrow Associates
mkreps@darrowir.com
214-597-8200

FAQ

When will Cingulate participate in the Benzinga All Access event?

Cingulate will participate in the Benzinga All Access event on August 28, 2024, at 10:30 a.m. CST.

Who will represent Cingulate at the Benzinga All Access event?

Chairman and CEO Shane J. Schaffer, PharmD, will represent Cingulate at the event.

Where can I watch the Cingulate presentation at Benzinga All Access?

You can watch the Cingulate presentation live on Benzinga's YouTube channel and later on Cingulate's website.

What topics will be discussed by Cingulate at the Benzinga All Access event?

Cingulate will discuss their recent European patent, the state of the ADHD market, and the potential expansion of their Precision Timed Release™ (PTR™) platform into other therapeutic areas.

What is the stock symbol for Cingulate?

The stock symbol for Cingulate is CING.